Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

• Published in: Blood Vol. 131; no. 17; pp. 1910 - 1919
• Main Authors: O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.04.2018; American Society of Hematology
• Subjects: Adenine - analogs & derivatives; Adult; Aged; Aged, 80 and over; Clinical Trials and Observations; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Male; Middle Aged; Piperidines; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Survival Rate

We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naïve (TN) older patients (≥65 years of age) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We now report on long-term effi...